Biogen confirms Icahn ally is on board - Atlanta Business Chronicle:

http://karatelifestudios.com/karate/juniors710.html
Shareholders were to elec four directors atthe meeting. Biogen was pushinh for the reelection of all ofthe company’s existinyg directors, while Icahn was angling to seat four new According to Biogen Idec, shareholders appeard to have reelected current directors Robert Pangia and William D. and elected Icahn ally Alexandere Denner. Biogen Idec officials say the vote for the fourtu seat is too close to Biogen said the company will rely on the tabulationm of votes by its independent inspectoreof elections, IVS before announcing the remaining directo r to serve on the Bruce R.
Ross, Biogen Idec’s chairman, said, “We welcome our new directofr to the board and look forward to workiny together to build on our strong trackj record of delivering While we await the outcome of the vote for theremainingh director, we would like to express our gratitude for the supporyt of our stockholders.” Icahn, in a filing with the Securities and Exchange Commission, accuses the company of preventing the votex cast from being counted. “If the board is successful, Richard Mulligan, a prominent scientist and physician, may be kept from legitimatelyt being elected tothe board.
” Mulligan is the Mallinckrodtg Professor of Genetics at Harvard Medicakl School and director of the Harvard Gene Therapy Initiative, according to Harvardr University’s Web site. Biogen said shareholders rejected severalof Icahn’s other including moving the company’z incorporation from Delaware to North a move Icahn said would give more powetr to shareholders. Biogen officials said it appears that stockholders also rejected a proposal by Icahn to limit the size of the boars to13 directors. Biogen officials now have the power to enlargew the board as theysee fit. Icahn is best knowjn for unsuccessfully pushing BiogemnIdec (Nasdaq: BIIB) to sell itself in 2008.
Last year, shareholders elected the company’s nominees over the slate of investorws put upby Icahn. Biogen Idec’s (NASDAQ: BIIB) stock was trading at $53.17 in afternoon trading Thursday, down from the previou day’s close of $53.43 a share.